Kimia Biosciences Ltd. engages in the manufacture and distribution of pharmaceutical products. The company is headquartered in New Delhi, Delhi and currently employs 241 full-time employees. The company went IPO on 2016-03-21. The firm provides its products under various categories: active pharmaceutical ingredients (APIs), intermediates and formulations. The firm's commercial products include acotiamide hydrochloride hydrate, azelnidipine, benfotiamine, benidipine hydrochloride, citicoline sodium, gliclazide, levosulpiride, luliconazole, oxaceprol, prucalopride succinate, teneligliptin hydrobromide hydrate, vildagliptin, fimasartantrihydrate potassium, obeticholic acid and ursodeoxycholic acid.

530313.BO Profile, Market Tickers and Other

530313.BO profile